Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Completed · Phase 2 · NCT04362501
Conditions: Chronic Sinusitis
At a glance
- Research payments reported, 2025
- $435,332
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 33
About the trial
- Sponsor
- Johns Hopkins University (with Regeneron Pharmaceuticals)
- Tested
- dupilumab (biological), placebo (drug)
- Dates
- Started 2020-10-15; completion 2025-09-30
- Results posted
- Not yet
The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has previously been determined. The additional information gained from secondary and exploratory outcomes will help provide important insight for applied research studies and may also provide practical guidance to clinicians on how to select patients for treatment.
From ClinicalTrials.gov, last updated 2025-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $435,332 in research payments for this study in 2025 (4 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Jhu School of Medicine $435,332
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.